Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Subscribe To Our Newsletter & Stay Updated
